A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Ryo,Kasahara ^[1] ; Takashi,Kawahara ^[2] ; Shinji,Ohtake ^[1] ; Yoko,Saitoh ^[3] ; Sohgo,Tsutsumi ^[1] ; Jun-Ichi,Teranishi ^[1] ; Yasuhide,Miyoshi ^[1] ; Noboru,Nakaigawa ^[1] ; Masahiro,Yao ^[1] ; Kazuki,Kobayashi ^[3] ; Hiroji,Uemura ^[3]

作者单位： Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan. ^[1] Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. ^[2] Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. ^[3]

主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);脱氧胞苷(Deoxycytidine);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);有机铂化合物(Organoplatinum Compounds);腰肌(Psoas Muscles);存活率(Survival Rate);膀胱肿瘤(Urinary Bladder Neoplasms)

DOI 10.1155/2017/7981549

PMID 28497065

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览8

BioMed research international

2017年2017卷

7981549页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

BioMed research international

相似文献

BioMed research international

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

BioMed research international

相似文献

BioMed research international

相关期刊

检索历史清除